Skip to main
UNCY

Unicycive Therapeutics (UNCY) Stock Forecast & Price Target

Unicycive Therapeutics (UNCY) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Unicycive Therapeutics Inc. is well-positioned for growth with its lead product candidate, Oxylanthanum Carbonate (OLC), which offers a convenient dosing regimen that may enhance patient compliance among approximately 500,000 individuals treated for hyperphosphatemia in the United States. Furthermore, the company's pipeline includes UNI-494, a new chemical entity with the potential to become a first-in-class treatment for Acute Kidney Injury, suggesting significant upside in Unicycive's market opportunities as the drug progresses through development. Additionally, analysts exhibit confidence in the company's trajectory, recognizing an expected improvement in market valuation as evidenced by a substantial increase in the proposed price target, indicating a positive outlook for Unicycive's stock.

Bears say

Unicycive Therapeutics has consistently incurred operating losses since its inception, indicating challenges in achieving profitability in the foreseeable future. Furthermore, pressures related to healthcare spending and potential unfavorable changes in reimbursement policies could adversely impact the company's financial performance and revenue projections. Additionally, the company is anticipated to require further capital to support its operations and development efforts, raising concerns about its long-term financial stability.

Unicycive Therapeutics (UNCY) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Unicycive Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Unicycive Therapeutics (UNCY) Forecast

Analysts have given Unicycive Therapeutics (UNCY) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Unicycive Therapeutics (UNCY) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Unicycive Therapeutics (UNCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.